%0 Journal Article
%T Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients
%A Mark S Walker
%A Murad Hasan
%A Yeun Mi Yim
%A Elaine Yu
%A Edward J Stepanski
%A Lee S Schwartzberg
%J Health and Quality of Life Outcomes
%D 2011
%I BioMed Central
%R 10.1186/1477-7525-9-46
%X HER-2 negative mBC patients (n = 102) were enrolled from 7 U.S. community oncology practices. Demographic, disease and treatment characteristics were abstracted from electronic medical records and linked to archived Patient Care Monitor (PCM) assessments. The PCM is a self-report measure of symptom burden and HRQoL administered as part of routine care in participating practices. Linear mixed models were used to examine change in PCM scores over time.Mean age was 57 years, with 72% of patients Caucasian, and 25% African American. Median time from mBC diagnosis to first disease progression was 8.8 months. Metastasis to bone (60%), lung (28%) and liver (26%) predominated at initial metastatic diagnosis. Results showed that PCM items assessing fatigue, physical pain and trouble sleeping were sensitive to either general effects of disease progression or to effects associated with specific sites of metastasis. Progression of disease was also associated with modest but significant worsening of General Physical Symptoms, Treatment Side Effects, Acute Distress and Impaired Performance index scores. In addition, there were marked detrimental effects of liver metastasis on Treatment Side Effects, and of brain metastasis on Acute Distress.Disease progression has a detrimental impact on cancer-related symptoms. Delaying disease progression may have a positive impact on patients' HRQoL.Breast cancer is the most common cancer among women in the United States (excluding skin cancer) and the second leading cause of cancer death in women (second to lung cancer)[1]. Although disease incidence in women decreased between 1999 and 2005, the incidence of advanced disease has remained stable[2].Few women (6%) diagnosed with breast cancer are initially diagnosed with distant metastases. Of those who are, 27.1% are alive after 5 years,[3] a rate considerably lower than the 5-year survival rate for women diagnosed with regional (84%) or localized (98%) disease[4]. In addition to those with ad
%U http://www.hqlo.com/content/9/1/46